Diagnocure, Inc.
OTC: DGCRF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Yves Fradet F.R.C.S.,
- Employees
- 3
- Headquarters
- Quebec, Canada
- IPO year
- 2009
- Market cap
- $21.5K
- Website
- https://www.diagnocure.com
Loading DGCRF…
Loading profile data…Frequently asked questions about DGCRF
What does Diagnocure, Inc. (DGCRF) do?
Diagnocure, Inc. is a Canadian life sciences company dedicated to developing and commercializing innovative products for cancer diagnosis. Its core business revolves around advanced molecular diagnostic tests designed for the identification and management of cancerous conditions. The company's portfolio includes the PCA3 test for prostate cancer...
Where does DGCRF trade?
Diagnocure, Inc. (DGCRF) trades on the Other OTC.
What sector is DGCRF in?
Diagnocure, Inc. (DGCRF) operates in the Healthcare sector, specifically in the Medical - Specialties industry.
Who is the CEO of Diagnocure, Inc.?
Yves Fradet F.R.C.S., is the chief executive officer of Diagnocure, Inc. (DGCRF).
Where is Diagnocure, Inc. headquartered?
Diagnocure, Inc. is headquartered in Canada.
Does DGCRF pay a dividend?
Diagnocure, Inc. (DGCRF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DGCRF go public?
Diagnocure, Inc. (DGCRF) completed its initial public offering in 2009.